Zhang Hong, Zhang Jiudan, Jiang Anna, Ni Haixiang
Department of Endocrinology and Metabolism, The First Affiliated Hospital Of ZheJiang Chinese Medical University, Hangzhou, Zhejiang 310009, China.
Department of Endocrinology and Metabolism, The First Affiliated Hospital Of ZheJiang Chinese Medical University, Hangzhou, Zhejiang 310009, China.
Gastroenterol Hepatol. 2019 Aug-Sep;42(7):413-422. doi: 10.1016/j.gastrohep.2019.01.008. Epub 2019 Apr 4.
To assess the efficacy and safety of gastric peroral endoscopic myotomy for the treatment of gastroparesis.
PubMed, Embase, Cochrane Library and Web of Science databases were searched from their earliest records to May 2018. The evaluation of clinical efficacy and safety was based on gastric emptying scintigraphy normalization, the improvement in clinical symptoms and adverse event rate. R 3.5.0 software was used to calculate the pooled estimate rates by meta-analysis. The improvement rate of the Gastroparesis Cardinal Symptom Index score was analyzed at different follow-up times.
Fourteen studies with a total of 276 patients were included in this systematic review. The pooled gastric emptying scintigraphy normalization rate was 61.3% (95% CI, 51.5-70.8%) and clinical symptom improvement rate was 88.2% (95% CI, 83.6-93.1%). Intra-operative complications were found in about 3.2% (95% CI, 0.1-4.2%) of all included patients, and postoperative adverse events in 2.1% (95% CI, 0.3-4.8%). The mean Gastroparesis Cardinal Symptom Index score improvement rate was about 90.2% at one month follow-up, 83.3% at three months, 70.3% at six months, 52.4% at twelve months and 57.1% at eighteen months.
Our systematic review demonstrates that gastric peroral endoscopic myotomy is a safe and effective treatment for gastroparesis. Though the short-term outcomes are promising, prospective, randomized, controlled studies with large sample size and long-term follow-up are required to further confirm these results.
评估经口内镜下胃肌切开术治疗胃轻瘫的疗效和安全性。
检索PubMed、Embase、Cochrane图书馆和Web of Science数据库,检索时间从各数据库最早记录至2018年5月。基于胃排空闪烁扫描正常化、临床症状改善情况和不良事件发生率对临床疗效和安全性进行评估。使用R 3.5.0软件通过荟萃分析计算合并估计率。分析不同随访时间胃轻瘫主要症状指数评分的改善率。
本系统评价纳入了14项研究,共276例患者。胃排空闪烁扫描正常化的合并率为61.3%(95%CI,51.5 - 70.8%),临床症状改善率为88.2%(95%CI,83.6 - 93.1%)。在所有纳入患者中,术中并发症发生率约为3.2%(95%CI,0.1 - 4.2%),术后不良事件发生率为2.1%(95%CI,0.3 - 4.8%)。随访1个月时,胃轻瘫主要症状指数评分的平均改善率约为90.2%,3个月时为83.3%,6个月时为70.3% , 12个月时为52.4%,18个月时为57.1%。
我们的系统评价表明,经口内镜下胃肌切开术是治疗胃轻瘫的一种安全有效的方法。尽管短期结果令人满意,但仍需要大样本量和长期随访的前瞻性随机对照研究来进一步证实这些结果。